Medical School

  • Johns Hopkins University , Baltimore , MD


  • Johns Hopkins University , Baltimore , MD


  • Johns Hopkins University , Baltimore , MD


  • Boston Children's Hospital , Boston , MA


  • American Board of Pediatrics, Pediatric Pulmonology


Publications powered by Harvard Catalyst Profiles

  1. Lung transplant referral practice patterns: a survey of cystic fibrosis physicians and general pulmonologists. BMC Pulm Med. 2020 Mar 04; 20(1):58. View abstract
  2. US pediatric pulmonology workforce. Pediatr Pulmonol. 2019 04; 54(4):444-450. View abstract
  3. Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis. BMJ Open Respir Res. 2015; 2(1):e000100. View abstract
  4. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33. View abstract
  5. Congenital pulmonary malformations in pediatric patients: review and update on etiology, classification, and imaging findings. Radiol Clin North Am. 2011 Sep; 49(5):921-48. View abstract
  6. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012 Jan; 67(1):12-8. View abstract
  7. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. J Inherit Metab Dis. 2010 Oct; 33(Suppl 2):S255-61. View abstract
  8. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther. 2007 Aug; 18(8):726-32. View abstract
  9. Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. Pediatrics. 2006 Sep; 118(3):1260-5. View abstract
  10. Species-specific bacteria identification using differential mobility spectrometry and bioinformatics pattern recognition. Anal Chem. 2005 Sep 15; 77(18):5930-7. View abstract
  11. Sweat testing infants detected by cystic fibrosis newborn screening. J Pediatr. 2005 Sep; 147(3 Suppl):S69-72. View abstract
  12. Challenges in implementing a successful newborn cystic fibrosis screening program. J Pediatr. 2005 Sep; 147(3 Suppl):S89-93. View abstract
  13. Communications systems and their models: Massachusetts parent compliance with recommended specialty care after positive cystic fibrosis newborn screening result. J Pediatr. 2005 Sep; 147(3 Suppl):S98-100. View abstract
  14. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004 Jun; 113(6):1573-81. View abstract
  15. Genetic counseling after implementation of statewide cystic fibrosis newborn screening: Two years' experience in one medical center. Genet Med. 2001 Nov-Dec; 3(6):411-5. View abstract
  16. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum Gene Ther. 2001 Jul 20; 12(11):1369-82. View abstract
  17. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum Gene Ther. 2001 Jul 20; 12(11):1383-94. View abstract
  18. Practice of pediatric pulmonology: results of the Future of Pediatric Education Project (FOPE) Pediatr Pulmonol. 2000 Sep; 30(3):190-7. View abstract
  19. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J. 1999 Mar; 18(3):223-31. View abstract
  20. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr. 1997 Jul; 131(1 Pt 1):118-24. View abstract
  21. Interpretation of respiratory input impedance in healthy infants. Pediatr Pulmonol. 1996 Dec; 22(6):364-75. View abstract
  22. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med. 1995 Jul; 152(1):157-62. View abstract
  23. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology. 1995 Feb; 108(2):584-92. View abstract
  24. Consensus conference: practical applications of Pulmozyme. September 22, 1993. Pediatr Pulmonol. 1994 Jun; 17(6):404-8. View abstract
  25. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993 Jul; 148(1):145-51. View abstract
  26. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993 Jun 17; 328(24):1740-6. View abstract
  27. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet. 1993 Feb; 2(2):159-63. View abstract
  28. Expression of normal and cystic fibrosis phenotypes by continuous airway epithelial cell lines. Am J Physiol. 1990 Dec; 259(6 Pt 1):L496-505. View abstract
  29. Respiratory impedance and multibreath N2 washout in healthy, asthmatic, and cystic fibrosis subjects. J Appl Physiol (1985). 1990 May; 68(5):2139-49. View abstract
  30. Density dependence of respiratory system impedances between 5 and 320 Hz in humans. J Appl Physiol (1985). 1989 Dec; 67(6):2323-30. View abstract
  31. Human respiratory input impedance from 4 to 200 Hz: physiological and modeling considerations. J Appl Physiol (1985). 1988 Feb; 64(2):823-31. View abstract
  32. Inverse modeling of dog airway and respiratory system impedances. J Appl Physiol (1985). 1987 Jun; 62(6):2273-82. View abstract
  33. Undesirable marketing practices in the pharmaceutical industry. N Engl J Med. 1985 Jul 04; 313(1):54. View abstract
  34. Respiratory system impedance from 4 to 40 Hz in paralyzed intubated infants with respiratory disease. J Clin Invest. 1983 Sep; 72(3):903-10. View abstract
  35. CT appearance of the liver in a patient with biliary cirrhosis and cystic fibrosis. J Comput Assist Tomogr. 1983 Jun; 7(3):530-3. View abstract
  36. Interaction of oscillatory and unidirectional flows in straight tubes and an airway cast. J Appl Physiol Respir Environ Exerc Physiol. 1982 Apr; 52(4):1097-1105. View abstract
  37. Airway area by acoustic reflections measured at the mouth. J Appl Physiol Respir Environ Exerc Physiol. 1980 May; 48(5):749-58. View abstract
  38. Yersinia enterocolitica septicemia. Am J Clin Pathol. 1978 Feb; 69(2):189-92. View abstract
  39. Increased nerve-growth-factor beta-chain cross-reacting material in familial dysautonomia. N Engl J Med. 1976 Sep 16; 295(12):629-34. View abstract
  40. An investigation of some factors affecting levels of erythrocyte inorganic pyrophosphatase activity. Clin Chim Acta. 1975 May 15; 61(1):27-37. View abstract
  41. Studies on human erythrocyte inorganic pyrophosphatase. Ann Hum Genet. 1974 Jan; 37(3):341-53. View abstract